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Abstract

Methods

Pregnancy Outcomes

Data for the NPR were collected via questionnaires, phone
The purpose of this study is to analyze pregnancy
outcomes reported to the Neoral® Pregnancy registry interviews and direct patient recruitment. Data for the transplant
(NPR) which collects data from women with psoriasis population were provided by the NTPR.

or rheumatoid arthritis who have taken Neoral®
(cyclosporine, USP MODIFIED) during pregnancy.
Since the NPR’s establishment, the NPR has recorded
10 live births, 1 ectopic pregnancy, with no premature
deliveries. The mean birth weight of the infants (BW)
was 3516.7 + 518 g. By comparison, the National
Transplantation Pregnancy Registry (NTPR) reports a
cohort of 129 female kidney transplant recipients taking
Neoral® during pregnancy with 158 livebirths, with a
BW of 2541 + 703 g; 48% were premature deliveries
(<37 wks). In conclusion, these findings suggest the
need for additional studies to further evaluate the
impact of comorbidities and other factors on
pregnancy outcomes in two disparate populations
maintained on the same immunosuppressive agent
during pregnancy.

Introduction
Cyclosporine A (CsA) was initially used as successful
therapy against organ rejection and as a result, the
transplant literature was the first to describe its use
during pregnancy. In the transplant population, CsA
exposure has been associated with premature delivery,
low birthweight and higher incidences of comorbidities
during pregnancy than the general population.
However, it has yet to be determined if these adverse
outcomes are directly related to CsA exposure during
pregnancy or to maternal comorbidities regardless of
therapy, or to both. Transplant recipients are
maintained on multiple drug regimens which further
complicates analyses.
In 1997, The Food and Drug Administration approved
Neoral® (cyclosporine, USP MODIFIED) for use in
severe psoriasis, an autoimmune disease not
associated with significant comorbidities and where
patients rarely take multiple systemic medications.
The purpose of this study was to assess the role of
comorbidities and other factors in the pregnancy
outcomes of women taking Neoral® by comparing data
from two disparate populations; kidney transplant
recipients and psoriasis patients.

• Cyclosporine exposure during pregnancy in the
transplant population does appear to be
associated with premature delivery and low
infant birthweight.

Only data from pregnant women taking Neoral® (cyclosporine,
USP MODIFIED) were used for this study.

• Data from the NPR show that cyclosporine

Results
• The mean gestational age for the psoriasis population is

Figure 1:
Comparison of
pregnancy
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transplant patients
and those with
psoriasis

significantly higher than that of kidney transplant population
(p value 0.001).

• The mean birth weight for psoriasis population is significantly
higher than that of the kidney transplant population
(p value 0.001)

• The kidney transplant population had a higher prevalence of

± 5.0 yrs

• CsA: Cyclosporine A
• NPR: Neoral® Pregnancy Registry
• NTPR: National Transplantation Pregnancy

Maternal Factors
Pregnancy Data

* Outcomes include twins

as multiple drug regimens, likely play a role in
the higher rates of premature delivery and low
birthweight infants in the kidney transplant
population (Figure 2).

Abbreviations

• Mean maternal age for the psoriasis population is 29.9 ± 2.7 yrs

Registry
• HTN: Hypertension
• DM: Diabetes Mellitus

Psoriasis
Patients
11
0%
0%
9.1%
0%
90.9%
40 ± 0.8 wks
0%
3517 ± 518 g
0%

• Maternal comorbidities or other factors, such

the impact of comorbidities and other factors
on pregnancy outcomes of women taking
Neoral®.

• Mean maternal age for the kidney transplant population is 31.4

Outcomes*
Therapeutic Abortions
Spontaneous abortions
Ectopic
Stillborn
Livebirths
Mean gestational age
Premature (<37 weeks)
Mean Birthweight
Low Birthweight (<2500g)

exposure during pregnancy in women with
psoriasis does not appear to be associated with
low gestational age or low infant birthweight
(Figure 1).

• Further investigation is warranted to evaluate

significant comorbidities such as drug-related hypertension,
infections, preeclampsia and gestational diabetes than both the
psoriasis patients and the US general population.

Kidney
Transplant
Recipients
199
2 (1%)
35 (18%)
1 (0.5%)
3 (1.5%)
158 (79%)
36 ± 2.9 wks
71 (48%)
2541 ± 703 g
67 (43%)

Conclusions

Figure 2:
Prevalence of
maternal
complications
during pregnancy:
A comparison of
maternal comorbidities
between the transplant
population and
psoriasis population,
both taking Neoral®.

To contact the NPR and report additional
pregnancies:
Thomas Jefferson University
1025 Walnut Street, 605 College Building,
Philadelphia, PA 19107, USA
Phone: Toll-free 888-522-5581
Email: Neoral.Registry@jefferson.edu
Website: http://www.jefferson.edu/neoral
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